Table 2.
Patient Population by TNM Stage/Primary Treatment, American Joint Committee on Cancer 8th Edition Clinical Prognostic Staging and 8th Edition Pathologic Prognostic Staging
| Cancer type, AJCC 8th edition clinical prognostic stage, pathologic prognostic stage | n | % | Pathologic upstaging |
|---|---|---|---|
| ER+ DCIS (n = 83,754) | |||
| 0 | |||
| 0 | 75,024 | 89.6 | Same stage |
| IA | 5,561 | 6.6 | Upstage |
| IB | 252 | 0.3 | Upstage |
| IIA-B | 162 | 0.4 | Upstage |
| IIIA-C | 46 | 0.0 | Upstage |
| Unknown | 2,709 | 3.2 | Upstage |
| ER– DCIS (n = 15,995) | |||
| 0 | |||
| 0 | 13,175 | 82.4 | Same stage |
| IA | 922 | 5.8 | Upstage |
| IB | 590 | 3.6 | Upstage |
| IIA-B | 298 | 1.9 | Upstage |
| IIIA-C | 81 | 0.5 | Upstage |
| Unknown | 1,926 | 5.8 | Upstage |
| cT1N0 NET (n = 1,395) | |||
| IA | 1,375 | 98.6 | — |
| 0 | 30 | 2.2 | Downstage |
| IA | 1,222 | 88.9 | Same stage |
| IB | 79 | 5.7 | Upstage |
| IIA-B | 33 | 2.4 | Upstage |
| IIIA-C | 11 | 0.8 | Upstage |
| IB | 20 | 1.4 | — |
| 0 | 0 | 0 | Downstage |
| IA | 8 | 40.0 | Downstage |
| IB | 0 | 0 | Same stage |
| IIA-B | 11 | 55.0 | Upstage |
| IIIA-C | 1 | 5.0 | Upstage |
| cT1N0 upfront operation (n = 209,102) | |||
| IA | 204,944 | 98.0 | — |
| 0 | 587 | 0.3 | Downstage |
| IA | 189,159 | 92.3 | Same stage |
| IB | 10,740 | 5.2 | Upstage |
| IIA-B | 2,776 | 1.7 | Upstage |
| IIIA-C | 888 | 0.4 | Upstage |
| IB | 4,158 | 2.0 | — |
| 0 | 11 | 0.3 | Downstage |
| IA | 2,917 | 70.2 | Downstage |
| IB | 0 | 0 | Same stage |
| IIA-B | 1,125 | 27.1 | Upstage |
| IIIA-C | 106 | 2.5 | Upstage |
| cT2N0 NET (n = 1,649) | |||
| IB | 1,288 | 78.1 | — |
| 0 | 11 | 0.9 | Downstage |
| IA | 1,019 | 79.1 | Downstage |
| IB | 229 | 17.8 | Same stage |
| IIA-B | 0 | 0 | Upstage |
| IIIA-C | 29 | 2.3 | Upstage |
| IIA | 332 | 20.1 | — |
| 0 | 2 | 0.6 | Downstage |
| IA | 88 | 26.5 | Downstage |
| IB | 116 | 34.9 | Downstage |
| IIA | 79 | 23.8 | Same stage |
| IIB | 30 | 9.0 | Upstage |
| IIIA-C | 17 | 5.1 | Upstage |
| IIB | 29 | 1.8 | — |
| 0 | 0 | 0 | Downstage |
| IA | 8 | 27.6 | Downstage |
| IB | 0 | 0 | Downstage |
| IIA | 11 | 37.9 | Downstage |
| IIB | 7 | 24.1 | Same stage |
| IIIA-C | 3 | 10.3 | Upstage |
| cT2N0 upfront operation (n = 51,208) | |||
| IB | 33,648 | 65.7 | — |
| 0 | 39 | 0.1 | Downstage |
| IA | 24,929 | 74.1 | Downstage |
| IB | 8,061 | 24.0 | Same stage |
| IIA-B | 0 | 0 | Upstage |
| IIIA-C | 619 | 1.8 | Upstage |
| IIA | 14,831 | 29.0 | — |
| 0 | 6 | 0.0 | Downstage |
| IA | 1,997 | 13.5 | Downstage |
| IB | 6,454 | 43.5 | Downstage |
| IIA | 4,396 | 29.6 | Same stage |
| IIB | 1,412 | 9.5 | Upstage |
| IIIA-C | 566 | 3.9 | Upstage |
| IIB | 2,729 | 5.3 | — |
| 0 | 4 | 0.1 | Downstage |
| IA | 285 | 1.0 | Downstage |
| IB | 0 | 0 | Downstage |
| IIA | 1,746 | 64.0 | Downstage |
| IIB | 520 | 19.1 | Same stage |
| IIIA-C | 174 | 6.4 | Upstage |
AJCC, American Joint Committee on Cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.